Nivolumab-Induced Psoriasis in a Patient with Lung Cancer. Case Report

Česká verzia

Authors: A. Bernardová ¹; M. Salavec ¹; L. Krbal ²; K. Sokolová ¹
Authors place of work: Klinika nemocí kožních a pohlavních, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, přednosta doc. MUDr. Miloslav Salavec, CSc. ¹; Fingerlandův ústav patologie, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, přednosta prof. MUDr. Aleš Ryška, Ph. D. ²
Published in the journal: Čes-slov Derm, 97, 2022, No. 4, p. 164-168
Category: Case Reports

Summary

The authors describe the case of a 61-year-old female patient treated with nivolumab for non-small cell lung cancer with a sudden maculopapular exanthema involving the palms and soles. Both the histological examination and the clinical findings confirmed the diagnosis of psoriasis. Discontinuation of nivolumab and treatment with systemic corticosteroids led to regression of the skin findings. The authors report current knowledge on nivolumab-induced psoriasis.

Keywords:

nivolumab – Non-small cell lung cancer – induced psoriasis

Zdroje

1. BALAK, D. M., HAJDARBEGOVIC, E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl)., 2017, 7, p. 87–94.

2. BASAVARAJ, K. H., ASHOK, N. M., RASHMI, R. et al. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol., 2010, 49(12), p. 1351–1361.

3. BOLOGNIA, J. L., SCHAEFFER, J. V., CERRONI, L. Dermatology, Elsevier., 2018, p. 366–369, 372.

4. DE BOCK, M., HULSAERT, E., KRUSE, V. et al. Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. Case Rep Dermatol., 2018, 10(2), p. 190–197.

5. DI ALTOBRANDO, A., BRUNI, F., ALESSANDRINI, A. et al. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma. Dermatol Ther., 2020, 33(3), e13363.

6. ELOSUA-GONZÁLEZ, M., PAMPÍN-FRANCO, A., MAZZUCCHELLI- ESTEBAN, R. et al. A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy. Dermatol Online J., 2017, 15, p. 23.

7. FATTORE, D., ANNUNZIATA, M. C., PANARIELLO, L. et al. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer., 2019,110, p. 107–109.

8. FERRIS, R. L, BLUMENSCHEIN, G. Jr., FAYETTE, J. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med., 2016, 375(19), p. 1856–1867.

9. FINKELMEIER, F., WAIDMANN, O., TROJAN, J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther., 2018, 18(12), p. 1169–1175.

10. GLINOS, G. D., FISHER, W. S., MORR, C. S. et al. Nivolumab- induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma. JAAD Case Rep., 2021, 27(11), p. 74–77.

11. HERCOGOVÁ, J. et. al. Klinická dermatovenerologie. 1, díl, Praha: Mladá fronta 2019, s. 167. ISBN 978-80- 204-5321-1.

12. HOFMANN, L., FORSCHNER, A., LOQUAI, C. et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer., 2016, 60, p. 190–209.

13. KILLION, L., BEATTY, P., BYRNE, N. et al. Nivolumab Induced Psoriasis Successfully Treated With Acitretin. J Drugs Dermatol., 2021, 20(8), p. 911.

14. KOPPOLU, V., REKHA VASIGALA, V. K. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther., 2018, 14(6), p. 1167–1175.

15. MAYOR IBARUNGEN, A., ENRIQUE, E. A., DIANA, P. L. et al. Apremilast for immune checkpoint inhibitor- induced psoriasis: A case series. JAAD Case Rep., 2021, 11, p. 84–89. doi: 10.1016/j.jdcr.2021.03.015. PMID: 33948464; PMCID: PMC8079825.

16. SIBAUD, V., LEBOEUF, N. R., ROCHE, H. et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol., 2016, 26(5), p. 427–443.

17. ŠTORK, J. et al. Dermatovenerologie. 2. vyd. Praha: Galén, 2013, s. 185, ISBN 978-80-7262-898-8.

18. VIVAR, K. L., DESCHAINE, M., MESSINA, J. et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol., 2017, 44(4), p. 381–384.

19. https://www.ema.europa.eu/en/documents/product- information/opdivo-epar-product-information_ cs.pdf, p. 20.